Coloured Ties Announces Approval of Option Agreement with Superior, Grant of Options and Closing of Substantial Issuer Bid

Investing News NetworkYour trusted source for investing success

acceleron pharma 2023

Barclays Sees Upside in US Biopharma Industry
Biotech Investing

Barclays Sees Upside in US Biopharma Industry

Biotech Investing

Celgene Receives FDA Approval for REBLOZYL

Biotech Investing

Celgene and Acceleration Pharma Announce Submission of Luspatercept Biologics License Application to FDA

Pharmaceutical Investing

Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study

MARKETS

Markets
TSX20714.48+13.98
TSXV622.01+0.87
DOW33978.08+28.67
S&P 5004070.56+10.13
NASD11621.71+109.30
ASX7493.80+25.50

COMMODITIES

Commodities
Gold1927.96+0.24
Silver23.60+0.01
Copper4.23-0.04
Palladium1713.170.00
Platinum1087.260.00
Oil79.38-1.63
Heating Oil3.19-0.11
Natural Gas2.85-0.09

DOWNLOAD FREE REPORTS

NEW! 2023 Critical Metals Outlook.

NEW! 2023 Agriculture Outlook Report

NEW! 2023 Rare Earths Outlook: Australia Edition

NEW! 2023 Zinc Outlook Report

NEW! 2023 Lithium Investor Report

Browse more resource reports ≫

NEW! 2023 Cleantech Outlook Report

Emerging Tech Outlook 2023

NEW! 2023 AI Outlook Report

NEW! 2023 Crypto Outlook Report

Start Here – Investing in Crypto

Browse more technology reports ≫

NEW! 2023 Pharmaceuticals Outlook Report.

FREE 2023 Psychedelics Investor Report

NEW! 2023 Biotech Outlook Report.

NEW! 2023 Life Science Outlook Report.

Start Here – Investing in Pharma

Browse more life science reports ≫

BROWSE COMPANIES BY SECTOR

loader